In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA takes first step in possible reversal of ban on some peptides The Washington Post The Unregulated World of Peptides: A Legal Minefield for Providers Holt Law The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals BPC 157: The peptide with big claims and scant evidence STAT